OBJECTIVE: The objective of this study was to determine the costs of clinically significant postoperative pancreatic fistula (POPF) and to evaluate the cost-effectiveness of routine pasireotide use. SUMMARY OF BACKGROUND DATA: We recently completed a prospective randomized trial that demonstrated an 11.7% absolute risk reduction of clinically significant POPF with use of perioperative pasireotide in patients undergoing pancreaticoduodenectomy or distal pancreatectomy [POPF: pasireotide (n = 152), 9% vs placebo (n = 148), 21%; P = 0.006]. METHODS: An institutional modeling system was utilized to obtain total direct cost estimates from the 300 patients included in the trial. This system identified direct costs of hospitalization, physician fees, laboratory tests, invasive procedures, outpatient encounters, and readmissions. Total direct costs were calculated from the index admission to 90 days after resection. Costs were converted to Medicare proportional dollars (MP$). RESULTS: Clinically significant POPF occurred in 45 of the 300 randomized patients (15%). The mean total cost for all patients was MP$23,400 (MP$8,000 - MP$202,500). The mean cost for those who developed clinically significant POPF was MP$39,700 (MP$13,800 - MP$202,500) versus MP$20,500 (MP$8,000 - MP$62,900) for those who did not (P = 0.001). The mean cost of pasireotide within the treatment group (n = 152) was MP$3,300 (MP$300 - MP$3,800). The mean cost was lower in the pasireotide (n = 152) group than the placebo (n = 148) group; however, this did not reach statistical significance (pasireotide, MP$22,800 vs placebo, MP$23,900: P = 0.571). CONCLUSIONS: The development of POPF nearly doubled the total cost of pancreatic resection. In this randomized trial, the routine use of pasireotide significantly reduced the occurrence of POPF without increasing the overall cost of care.
RCT Entities:
OBJECTIVE: The objective of this study was to determine the costs of clinically significant postoperative pancreatic fistula (POPF) and to evaluate the cost-effectiveness of routine pasireotide use. SUMMARY OF BACKGROUND DATA: We recently completed a prospective randomized trial that demonstrated an 11.7% absolute risk reduction of clinically significant POPF with use of perioperative pasireotide in patients undergoing pancreaticoduodenectomy or distal pancreatectomy [POPF: pasireotide (n = 152), 9% vs placebo (n = 148), 21%; P = 0.006]. METHODS: An institutional modeling system was utilized to obtain total direct cost estimates from the 300 patients included in the trial. This system identified direct costs of hospitalization, physician fees, laboratory tests, invasive procedures, outpatient encounters, and readmissions. Total direct costs were calculated from the index admission to 90 days after resection. Costs were converted to Medicare proportional dollars (MP$). RESULTS: Clinically significant POPF occurred in 45 of the 300 randomized patients (15%). The mean total cost for all patients was MP$23,400 (MP$8,000 - MP$202,500). The mean cost for those who developed clinically significant POPF was MP$39,700 (MP$13,800 - MP$202,500) versus MP$20,500 (MP$8,000 - MP$62,900) for those who did not (P = 0.001). The mean cost of pasireotide within the treatment group (n = 152) was MP$3,300 (MP$300 - MP$3,800). The mean cost was lower in the pasireotide (n = 152) group than the placebo (n = 148) group; however, this did not reach statistical significance (pasireotide, MP$22,800 vs placebo, MP$23,900: P = 0.571). CONCLUSIONS: The development of POPF nearly doubled the total cost of pancreatic resection. In this randomized trial, the routine use of pasireotide significantly reduced the occurrence of POPF without increasing the overall cost of care.
Authors: Jordan M Winter; John L Cameron; Kurtis A Campbell; David C Chang; Taylor S Riall; Richard D Schulick; Michael A Choti; JoAnn Coleman; Mary B Hodgin; Patricia K Sauter; Christopher J Sonnenday; Christopher L Wolfgang; Michael R Marohn; Charles J Yeo Journal: J Gastrointest Surg Date: 2006-11 Impact factor: 3.452
Authors: Jordan M Winter; John L Cameron; Kurtis A Campbell; Meghan A Arnold; David C Chang; Joann Coleman; Mary B Hodgin; Patricia K Sauter; Ralph H Hruban; Taylor S Riall; Richard D Schulick; Michael A Choti; Keith D Lillemoe; Charles J Yeo Journal: J Gastrointest Surg Date: 2006-11 Impact factor: 3.452
Authors: C Kristian Enestvedt; Brian S Diggs; Maria A Cassera; Chet Hammill; Paul D Hansen; Ronald F Wolf Journal: Am J Surg Date: 2012-03-29 Impact factor: 2.565
Authors: C J Yeo; J L Cameron; M M Maher; P K Sauter; M L Zahurak; M A Talamini; K D Lillemoe; H A Pitt Journal: Ann Surg Date: 1995-10 Impact factor: 12.969
Authors: Yael Vin; Camelia S Sima; George I Getrajdman; Karen T Brown; Anne Covey; Murray F Brennan; Peter J Allen Journal: J Am Coll Surg Date: 2008-06-30 Impact factor: 6.113
Authors: James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier Journal: Pancreas Date: 2020-01 Impact factor: 3.327
Authors: Jason W Denbo; Morgan Bruno; Whitney Dewhurst; Michael P Kim; Ching-Wei Tzeng; Thomas A Aloia; Jose Soliz; Barbara Bryce Speer; Jeffrey E Lee; Matthew H G Katz Journal: Surgery Date: 2018-05-25 Impact factor: 3.982
Authors: June S Peng; Daniel Joyce; Maureen Brady; Adrienne Groman; Kristopher Attwood; Boris Kuvshinoff; Steven N Hochwald; Moshim Kukar Journal: J Surg Oncol Date: 2020-05-30 Impact factor: 3.454
Authors: Jason W Denbo; Rebecca S Slack; Morgan Bruno; Jordan M Cloyd; Laura Prakash; Jason B Fleming; Michael P Kim; Thomas A Aloia; Jean-Nicolas Vauthey; Jeffrey E Lee; Matthew H G Katz Journal: J Gastrointest Surg Date: 2017-01-03 Impact factor: 3.452
Authors: Ryan J Ellis; D Brock Hewitt; Jason B Liu; Mark E Cohen; Ryan P Merkow; David J Bentrem; Karl Y Bilimoria; Anthony D Yang Journal: J Surg Oncol Date: 2019-04-05 Impact factor: 3.454